Fasting glucagon concentrations are associated with longitudinal decline of β-cell function in non-diabetic humans

Purpose: Abnormal glucagon concentrations are a feature of prediabetes but it is uncertain if alpha-cell dysfunction contributes to a longitudinal decline in beta-cell function. We therefore sought to determine if a decline in beta-cell function is associated with a higher nadir glucagon in the postprandial period or with higher fasting glucagon. Methods: This was a longitudinal study in which 73 non-diabetic subjects were studied on 2 occasions 6.6 +/- 0.3 years apart using a 2-hour, 7-sample oral glucose tolerance test. Disposition Index (DI) was calculated using the oral minimal model applied to the measurements of glucose, insulin, C-peptide concentrations during the studies. We subsequently examined the relationship of glucagon concentrations at baseline with change in DI (used as a measure of beta-cell function) after adjusting for changes in weight and the baseline value of DI. Results: After adjusting for covariates, nadir postprandial glucagon concentrations were not associated with changes in beta-cell function as quantified by DI. On the other hand, fasting glucagon concentrations during the baseline study were inversely correlated with longitudinal changes in DI. Conclusions: Defects in alpha-cell function, manifest as elevated fasting glucagon, are associated with a subsequent decline in beta-cell function. It remains to be ascertained if abnormal alpha-cell function contributes directly to loss of beta-cell secretory capacity in the pathogenesis of type 2 diabetes. (C) 2020 Elsevier Inc. All rights reserved.